Long Term Immunity and Safety Following Vaccination With the Japanese Encephalitis Vaccine IC51(IXIARO®, JESPECT®) In a Pediatric Population in Non Endemic Countries. Uncontrolled, Phase 3 Follow-up Study
Phase of Trial: Phase III
Latest Information Update: 04 May 2015
At a glance
- Drugs IC 51 (Primary)
- Indications Japanese encephalitis
- Focus Pharmacodynamics
- Sponsors Valneva
- 04 Mar 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
- 05 Dec 2013 Planned end date changed from 1 Mar 2015 to 1 Jun 2015 as reported by ClinicalTrials.gov.
- 17 Feb 2013 New trial record